MKMaxim V. Khoroshilov

Maxim V. Khoroshilov

*This is an algorithmically generated author record based on publicly available information.

Maxim V. Khoroshilov has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Camrelizumab combined with dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: first results of the prospective CAMELLA study

    by E. V. Artamonova, T. A. Titova, M. V. Khoroshilov, E. I. Kovalenko, A. V. Petrovsky, Е. В. Артамонова, Т. А. Титова, М. В. Хорошилов, Е. И. Коваленко, А. В. Петровский

    Triple-negative breast cancer (TNBC) accounts for approximately 15 % of all breast cancer cases and is characterised by an aggressive course and an increased risk of early relapse. Pathological complete response (pCR) after neoadjuvant treatment is associated with improved long-term outcome. The addition of PD‑1 inhibitors to neoadjuvant chemotherapy increases pCR and improves survival, making chemoimmunotherapy a treatment option for early and locally advanced TNBC. The review section covers KEYNOTE‑522, GeparNuevo and CamRelief and the rationale for camrelizumab in the Russian healthcare setting. CAMELLA (NCT07107217) is a prospective, open-label, non-randomised multicentre phase II study combining camrelizumab with dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel/carboplatin. This interim single-centre analysis includes 25 evaluable patients. Nineteen patients underwent surgery and definitive pathological results were available for 16. pCR was achieved in 12 of 16 patients (75.0 %; exact 95 % CI 47.6–92.7), RCB-I in 3 (18.8 %), and RCB-II in 1 (6.3 %); the combined RCB 0–I rate was 93.8 % (15/16; exact 95 % CI 69.8–99.8). Among 13 initially node-positive patients with pathology available, nodal pCR was observed in 12 (92.3 %). Cohort-level administered-dose ratios were 100.0 % for doxorubicin and cyclophosphamide, 97.5 % for paclitaxel, 81.2 % for carboplatin, and 94.5 % for camrelizumab; time-adjusted relative dose intensities were 94.4 %, 94.4 %, 90.5 %, 75.9 %, and 87.4 %, respectively. Grade 3–4 neutropenia was documented in 9/25 (36.0 %) patients, reactive cutaneous capillary endothelial proliferation in 23/25 (92.0 %), and grade 2 hypothyroidism in 10/25 (40.0 %). Four patients discontinued the second chemotherapy block early due to toxicity and one withdrew from further chemotherapy. These data reproduce the results of the CamRelief registration trial in Russian clinical practice and with a dose-dense chemotherapy backbone.

  • Neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer

    by A. R. Minnibaeva, E. V. Artamonova, Ya. A. Zhulikov, M. V. Khoroshilov, E. I. Kovalenko

    The widespread use of anti-HER2 drugs has fundamentally changed the fate of patients with both early and metastatic HER2-positive breast cancer (BC). The results of clinical studies demonstrate a significant increase in the frequency of achieving complete pathological response (pCR) and, as a consequence, improved survival rates when using the combination of docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP) in neoadjuvant chemotherapy for HER2+ breast cancer, which is reflected in modern domestic and international guidelines. The purpose of this study was to evaluate the effectiveness of the TCHP regimen, as well as to identify independent clinical and morphological factors in achieving pCR. The study included 234 patients with HER2-positive breast cancer of stages II and III who received TCHP regimen in neoadjuvant setting, 233 were operated. The rate of achieving complete pathomorphological response (pCR, RCB 0) was 63 %, in the nonluminal HER2-positive subtype – 76 %, in the luminal HER2-positive subtype – 55 %. Predictors of pCR were the absence of hormonal receptors in the tumor (OR = 1.72; 95 % CI: 1.17–2.54; р = 0,01), as well as a high (>50 %) Ki-67 proliferation index (OR = 1.4; 95 % CI: 1.01–1.98; р = 0,05). The use of granulocyte colony stimulating factor as primary prevention has reduced the risk of febrile neutropenia and mucositis. Further observation of patients will allow us to evaluate the long-term results of neoadjuvant therapy for HER2-positive breast cancer using the TCHP regimen in our population.


  • Open Access

    Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study

    by Tatiana N. Zabotina, Antonina I. Chertkova, Anna A. Borunova, Nikolay E. Kushlinskii, Elena S. Gershtein, Elena N. Zakharova, Esma K. Shoua, Vasily T. Tsiklauri, Igor V. Samoylenko, Maxim V. Khoroshilov, et al.

    Background. The PD-1/PD-L1 pathway plays an important role in tumor evasion from immunological surveillance. In addition to the membrane forms of PD-1 and PD-L1, there are soluble variants: sPD-1 and sPD-L1. Both membrane and soluble forms have immunoregulatory properties and can affect the function and number of different immune cell populations. Aim. To study the relationship between the initial level of CD8⁺PD-1⁺ and CD4+PD-1⁺ lymphocytes and soluble forms of sPD-1 and sPD-L1 with the percentage of the main effector and regulatory populations of peripheral blood (PB) lymphocytes and tumor-infiltrating lymphocytes. Materials and methods. The study included melanoma, breast cancer and the oral mucosa cancer patients. The percentage of cell populations of PB lymphocytes and tumor-infiltrating lymphocytes was determined by flow cytometry before treatment. The concentrations of sPD-1 and sPD-L1 proteins were studied in blood serum using enzyme immunoassay. Results. The relationship of the level of CD8⁺PD-1⁺ cells with certain populations of CD8-lymphocytes in PB and tumor tissue was found. In the PB of melanoma patients with CD8⁺CD11b⁺CD28⁺ and CD8⁺CD11b⁻CD28⁻ T cells, in breast cancer patients with a population of CD8⁺CD11b⁺CD28⁺ lymphocytes. In the tumor tissue of all patients there was a positive correlation with a population of regulatory CD8⁺CD11b⁻CD28⁻ T cells. The immunoregulatory properties of sPD-1 and sPD-L1 were confirmed. Both sPD-1 and sPD-L1 levels were positively correlated with the number of suppressor CD8⁺CD11b⁻CD28⁻ T cells and negatively with the level of CD8 lymphocytes, CD8⁺CD11b⁺CD28⁺ cytotoxic/memory T cells, B cells and activated CD25 lymphocytes. Conclusion. The results of the study can make a certain contribution to the study of the prognostic significance of membrane and soluble forms of PD-1 and PD-L1, taking into account the peculiarities of their relationship with suppressor and effector populations of lymphocytes of systemic and local immunity.


  • Efficacy of dose-dense versus standard neoadjuvant chemotherapy regimensin luminal HER2-negative breast cancer: Interim results of single-centre study

    by E. I. Kovalenko, Ya. A. Zhulikov, E. V. Artamonova, M. V. Khoroshilov, A. V. Petrovskiy, D. A. Denchik, I. K. Vorotnikov

    Introduction. The efficacy of dose-dense AC in adjuvant chemotherapy of luminal breast cancer (ER+ BC) compared with the standard dosing regimen followed by switching to taxanes has been proven in numerous clinical trials and in a large meta-analysis of the EBCTCG group. However, no study about efficiency of this regimen in neoadjuvant setting has been published.The aim of the study. To assess the effectiveness of dose-dense regimens of neoadjuvant chemotherapy (NAC) of ER + HER2-BC (4 AC once every 2 weeks (dose dense, ddAC), then 4 courses of Docetaxel once every 3 weeks or 12 weekly injections of Paclitaxel [4D/12P]) and their comparison with the standard ones (AC once every 3 weeks [ACq3w], hereinafter 4D/12P). Primary end points are complete response rate (pCR) and RCB0–I.Methods. This retrospective study included patients with resectable or locally advanced luminal HER2-negative breast cancer who received NAC from Janu 2017 to Aug 2022. Statistical hypothesis – the dose-dense regimen AC increases the frequency of RCB0–I from 22 to 32% compared to the standard dosing regimen with subsequent switching to taxanes, with a study power of 80%, ά = 0.05, 138 patients should be included in the study. A total of 315 patients were included in the study, of which 147 and 168 patients received dose-dense (ddAC) and standard chemotherapy (ACq3w), respectively. After propensity matching analysis 138 patients in each group were included in the final analysis.Results. The pCR rate was 18.84% in the ddAC group versus 14.49% in the AC q3w group, the differences were not statistically significant (p = 0.379). The frequency of RCB0–I was higher in the ddAC – group 33.33% versus 21.74% in the AC q3w (p = 0.040). According to the subgroup analysis, rate of RCB0–I was significantly higher in patients younger 50 years, cN0, with the expression of progesterone receptors in ≥ 20%.Conclusions. This is the first study to compare the efficacy of a ddAC NAC with a standard regimen for ER + HER2-BC. NAC with ddAC is associated with an increase in RCB0–I rate.

  • Dose-dense neoadjuvant chemotherapy of operable and locally advanced inoperable triple negative breast cancer: First results of single-centre prospective trial

    by E. I. Kovalenko, Ya. A. Zhulikov, E. V. Artamonova, M. V. Khoroshilov, A. V. Petrovskiy, D. A. Denchik, D. I. Drujinina, I. K. Vorotnikov

    Introduction. Neoadjuvant chemotherapy (NACT) is the standard of care for II–III stages of TN BC. Complete pathomorphological response (pCR) is associated with a signifiant increase in event-free and overall survival. In addition, in the absence of pCR, post-neoadjuvant adjuvant therapy is prescribed, while if pCR is achieved, additional treatment is not carried out. Despite a large number of studies on NACT of TN BC, different NACT regimens in various clinical trials make it diffiult to interpret their results.Objective. To investigate the effiacy of 4ddAC followed by 12 weekly cycles of paclitaxel and carboplatin in TN BC (according to the RCB system and the frequency of pCR); determine the predictive factors for the effectiveness of this chemotherapy regimen, and the effect of dose intensity on the pCR rate.Methods. This prospective study included 154 patients with TN breast cancer who received dose-dence neoadjuvant chemotherapy from January 2017 to March 2022.Results. PCR rate was 53.25 % (n = 82), RCB 0–I was 66.88 % (n = 103), disease progression was observed in 3.25 % (n = 4). The frequency of germline mutations in the BRCA1/2 genes was 21.43 % (n = 33). The most common mutation was BRCA1 5382insC – 63.64 % (n = 21) of all BRCA1/2 mutations. Rare mutations detected by NGS accounted for 30.3 % (n = 10). The only factor associated with a signifiant increase in the pCR rate was age ≤50 years (p = 0.010), there was a trend towards an increase pCR rate in the subgroups T1–2 (p = 0.052) and BRCA1/2 mut (p = 0.080). There was no effect of the dose intensity on the achievement of pCR.Conclusions. This retrospective analysis is the largest study evaluating the effiacy of 4 ddAC followed by 12 PC in NACT TN BC. The regimen allows to achieve a high frequency of pCR, despite the large proportion of patients with locally advanced breast cancer. The high frequency of rare mutations in the BRCA1/2 genes and the potential therapeutic signifiance of this marker in residual disease treatment dictates the need for NGS in all patients with TN in breast cancer.


  • Open Access

    Efficiency of chemotherapy GemCap + mitotane as second and subsequent lines of therapy for metastatic adrenocortical cancer

    by Ya. A. Zhulikov, E. I. Kovalenko, V. Yu. Bokhyan, M. V. Khoroshilov, D. A. Goryainov, A. A. Roslyakova, S. S. Magamedova, E. V. Evdokimova, E. V. Artamonova, В. Ю. Бохян

    Background. Combination of gemcitabine, metronomic capecitabine and mitotane (GemCap + m) is the most studied regimen in second and subsequent lines of therapy for advanced adrenocortical cancer (ACC). Previously published studies do not give a definitive answer to the question- what plays a key role in realizing the response to treatment: chemotherapy or mitotane in therapeutic concentration.Aim. Evaluation the efficacy and safety of GemCap + m combination with the standard dosing regimen of capecitabine in patients with metastatic ACC.Materials and methods. This retrospective single-center clinical study included patients over 18 years of age with histologically confirmed ACC with disease progression after completion of platinum-containing therapy. They received chemotherapy regimen gemcitabine 800 mg/m2 for days 1, 8 and capecitabine 1000 mg/m2 orally 2 times at days 1–14 of the 21-day cycle with mitotane. we evaluated objective response, stabilization of disease, 6-months disease control rate and median progression-free and overall survival. Radiological assessment according to RECIST 1.1 criteria was carried out every 6–8 weeks of treatment.Results. The study included 25 patients. mitotane concentration above 14 ng/mL was achieved in 22 (88 %) patients, of which 21 (84 %) reached therapeutic concentration in previous treatment lines. 80 % of patients received treatment as 2nd line, 20 % as 3rd and subsequent lines. The objective responses and disease stabilization was observed in 1 (4 %) and 11 (44 %) of patients, respectively. Disease control for at least 6 months rate was 24 %. median progression-free and overall survival were 3.2 months and 12.17 months, respectively. Toxicity grade 3–4 was observed in 28 % of patients. gemcitabine dose reductions due to thrombocytopenia grade 1–2 were required in 2 cases (8 %), no capecitabine reductions were necessary.Conclusion. This study demonstrates the effectiveness of a new dose regimen of chemotherapy GemCap + m in the second and subsequent lines of therapy for metastatic ACC. The progression of the disease against the background of previous lines of therapy at a therapeutic concentration of mitotane in the majority of patients indicates the effectiveness of the chemotherapeutic component of gemCap in a cohort of patients resistant to platinum and mitotane.

  • Use of peroral form of vinorelbine in metastatic breast cancer – choice in favor of quality of life

    by E. V. Lubennikova, M. V. Khoroshilov, N. C.-D. Drobot, E. V. Artamonova

    Применение пероральной формы винорелбина при метастатическом раке молочной железы – выбор в пользу качества жизни

  • Neoadjuvant chemotherapy for HER2-positive breast cancer using dose-consolidated regimens and dual anti-HER2 blockade with pertuzumab and trastuzumab (preliminary results)

    by E. I. Kovalenko, E. V. Artamonova, Ya. A. Zhulikov, M. V. Khoroshilov

    The main goal of neoadjuvant chemotherapy (NACT) in aggressive breast cancer (BC) subtypes (triple-negative, HER2-positive) is to achieve complete pathological response (pCR), since it is associated with a significant decrease in the likelihood of recurrence and death. Currently, the standard approach for HER2+ BC stage II–III is NACT with the inclusion of a double anti-HER2 blockade, since this significantly increases the frequency of pCR. To date, it remains unclear whether the intensification of modern anthracycline-taxane-containing regimens of NACT affects the incidence of pCR in different BC subtypes, including HER2-positive, provided that a double anti-HER2 blockade is used.The aim of our prospective observational study from daily clinical practice was to assess the efficacy (according to the RCB system and the frequency of pCR) and tolerability of dose-dense NACT in stage II–III HER2-positive BC.Materials and methods. The study included 86 patients, mean age 45 years (26–74 years), in 96.5% of cases, the tumor was represented morphologically by invasive cancer of a nonspecific type, in 53.5% of the tumors had a positive luminal B HER2 phenotype, in 46.5% – non-luminal HER2+. The majority of patients (67.4%) had locally advanced inoperable breast cancer; in 80.2% of cases, metastatic lesions of regional lymph nodes were determined. NACT included anthracyclines and taxanes: four cycles of AC in a dose-dense regimen (once every 2 weeks), then four cycles of docetaxel 75 mg/m2 once every 3 weeks + trastuzumab + pertuzumab.Results. The frequency of pCR = RCB0 in the entire group was 54.7% (47/86), in locally advanced breast cancer – 55.9%, in operable breast cancer – 51.9%. In the luminal HER2+ subtype, the frequency of pCR was lower than in the non-luminal HER2+ subtype – 43.5% vs 67.5%, however, the differences were statistically insignificant (p = 0.09). The frequency of RCB0–I in ER+ HER2+ subtype was 60.9%, as in ER-HER2+ – 80%. Conclusions. In our study, for the first time, the efficacy of dose-dense NACT in HER2+ breast cancer was assessed; it was shown that the frequency of pCR and RCB0–I correspond to those in standard anthracycline-taxane-containing regimens. In the context of the use of double anti-HER2 blockade, the anthracycline stage, most likely, does not need to be escalated, since this does not lead to an increase in the frequency of complete pathomorphological regressions.


  • Open Access

    RELATIONSHIP OF LYMPHOCYTE SUBPOPULATIONS IN BREAST CANCER PATIENTS WITH TREATMENT RESULTS

    by T. N. Zabotina, A. I. Chertkova, A. A. Borunova, E. N. Zakharova, E. K. Shoua, E. V. Artamonova, E. I. Kovalenko, M. V. Horoshilov, A. G. Kadagidze

    Introduction. Breast cancer (BC) is an immunogenic tumor. Immune cells infiltration of tumor tissue can affect the clinical course of the disease. The immunogenicity of breast cancer varies depending on the molecular subtype.The aim of this work was to study the main indicators of systemic and local immunity before patient’s treatment and to determine their relationship with the immediate neoadjuvant chemotherapy results.Materials and methods. Patients with stage II–III BC received standard neoadjuvant chemotherapy in accordance with the molecular subtypes. The percentage of the main effector and regulatory lymphocytes populations of systemic and local immunity was determined by flow cytometry.Results. A decrease in the level of effector CD8 and CD4 lymphocyte populations and an increase in the level suppressor populations in tumor tissue in comparison with peripheral blood indicate an immunosuppressive state of local immunity in BC patients. In tumor tissue, a high level of CD8+ PD-1+ and CD4+ PD-1+ cells were associated with a high level of regulatory CD4+ CD25highCD127–/low and CD8+ CD11b– CD28– lymphocytes. Differences were found in the significance of individual lymphocyte populations for the immediate results of treatment between patients with different subtypes of breast cancer.Conclusion. Determination of lymphocyte subpopulations correlating with the level of PD-1 cells, and the results of treatment in patients with different molecular BC subtypes, will help a clearer understanding of the antitumor immune response in this pathology, and will also serve as a basis for identifying immune biomarkers that can be used as additional predictive factors in various treatment options for BC patients.


  • Open Access

    Efficiency and tolerability of abemaciclib in elderly patients

    by E. I. Kovalenko, M. V. Khoroshilov, E. V. Artamonova

    Elderly cancer patients represent a very heterogeneous population not only in chronological age, but also in functional status, concomitant diseases and therapy, geriatric syndromes, and, as a consequence, in the tolerability of cancer treatment. The choice of treatment for metastatic breast cancer (mBC) in this category of patients is often a difficult task for oncologists. The emergence of a new class of drugs, inhibitors of cyclin-dependent kinases 4/6 (CDK4/6), has changed the paradigm of treatment of patients with luminal HER2 negative mBC (ER + HER2mBC); however, data on the efficacy and tolerability of these drugs in elderly patients are limited. Pooled subgroup analyzes of studies with CDK4/6 have shown that elderly patients with ER + HER2breast cancer have a clear PFS benefit from the addition of targeted drugs to hormonal therapy. Adverse events are observed more often in combination therapy with increasing age, which requires dose modification and appropriate therapy. In this regard, the drug abemaciclib is very attractive, which is characterized by a lower frequency of neutropenia compared to other CDK4/6 inhibitors, but a higher incidence of diarrhea, which can be controlled by taking appropriate drugs and is not a reason for treatment discontinuation. Careful selection of patients is necessary when deciding on the appointment of any therapy to geriatric cancer patients. Only a comprehensive multidisciplinary approach will make it possible to maximally individualize the approach to the treatment of this difficult category of patients and minimize the likelihood that they will receive excessive or insufficient oncological treatment.